People · Operator
Named in public records as an officer, director or promoter · active 2009–2009 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Watson Pharmaceuticals Inc | — | Pharmaceuticals | Growth/Late | $500.0M | $18.2B | 2009 |
Christopher W. Bodine at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christopher W. Bodine on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Andrew L. Turner | 1 | 3 |
| Albert F Hummel | 1 | 2 |
| Paul M. Bisaro | 1 | 2 |
| Catherine M. Klema | 1 | 2 |
| R. Todd M. Joyce | 1 | 1 |
| Ronald R. Taylor | 1 | 1 |
| David A. Buchen | 1 | 1 |
| Anthony W. Tabatznik | 1 | 1 |
| Michael J. Fedida | 1 | 1 |
| Fred G. Weiss | 1 | 1 |
| Michel J. Feldman | 1 | 1 |
| Jack M. Michelson | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.